Nothing Special   »   [go: up one dir, main page]

FR13C0072I1 - NEW VACCINE COMPOSITION - Google Patents

NEW VACCINE COMPOSITION

Info

Publication number
FR13C0072I1
FR13C0072I1 FR13C0072C FR13C0072C FR13C0072I1 FR 13C0072 I1 FR13C0072 I1 FR 13C0072I1 FR 13C0072 C FR13C0072 C FR 13C0072C FR 13C0072 C FR13C0072 C FR 13C0072C FR 13C0072 I1 FR13C0072 I1 FR 13C0072I1
Authority
FR
France
Prior art keywords
vaccine composition
new vaccine
new
composition
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0072C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxosmithkline Biologicals Niederlassung Der Smithkline Beecham Pharma Co Kg GmbH
Original Assignee
Glaxosmithkline Biologicals Niederlassung Der Smithkline Beecham Pharma Co Kg GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0113083A external-priority patent/GB0113083D0/en
Priority claimed from GB0204116A external-priority patent/GB0204116D0/en
Application filed by Glaxosmithkline Biologicals Niederlassung Der Smithkline Beecham Pharma Co Kg GmbH filed Critical Glaxosmithkline Biologicals Niederlassung Der Smithkline Beecham Pharma Co Kg GmbH
Publication of FR13C0072I1 publication Critical patent/FR13C0072I1/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FR13C0072C 2001-05-30 2013-12-18 NEW VACCINE COMPOSITION Active FR13C0072I1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0113083A GB0113083D0 (en) 2001-05-30 2001-05-30 Novel compounds
GB0204116A GB0204116D0 (en) 2002-02-21 2002-02-21 Novel vaccine composition
PCT/EP2002/005883 WO2002097072A2 (en) 2001-05-30 2002-05-29 Influenza vaccine composition

Publications (1)

Publication Number Publication Date
FR13C0072I1 true FR13C0072I1 (en) 2014-01-31

Family

ID=30445235

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0072C Active FR13C0072I1 (en) 2001-05-30 2013-12-18 NEW VACCINE COMPOSITION

Country Status (30)

Country Link
US (2) US7316813B2 (en)
EP (3) EP1407008B1 (en)
JP (1) JP4074582B2 (en)
KR (1) KR100871021B1 (en)
CN (2) CN1279165C (en)
AR (1) AR036039A1 (en)
AT (1) ATE420159T1 (en)
AU (2) AU2006200742C9 (en)
BR (1) BRPI0210076B8 (en)
CA (1) CA2448208C (en)
CO (1) CO5540349A2 (en)
CY (1) CY1108930T1 (en)
CZ (1) CZ298697B6 (en)
DE (1) DE60230760D1 (en)
DK (1) DK1407008T3 (en)
ES (1) ES2318020T3 (en)
FR (1) FR13C0072I1 (en)
HK (1) HK1067891A1 (en)
HU (1) HU229368B1 (en)
IL (2) IL158931A (en)
MX (1) MXPA03010944A (en)
MY (1) MY134424A (en)
NO (1) NO335212B1 (en)
NZ (1) NZ529755A (en)
PL (1) PL206435B1 (en)
PT (1) PT1407008E (en)
SI (1) SI1407008T1 (en)
TW (1) TWI228420B (en)
WO (1) WO2002097072A2 (en)
ZA (1) ZA200309250B (en)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1878424A3 (en) * 1999-09-24 2008-04-09 GlaxoSmithKline Biologicals S.A. Novel vaccine
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
KR101190932B1 (en) 2003-02-25 2012-10-16 메디뮨 엘엘씨 Methods of producing inflenza vaccine compositions
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
RS51665B (en) 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Decreasing potential iatrogenic risks associated with influenza vaccines
KR101376889B1 (en) * 2004-10-06 2014-03-25 메디뮨 엘엘씨 Refrigerator-temperature stable influenza vaccine compositions
CA2586690A1 (en) * 2004-11-03 2006-06-15 Novartis Vaccines And Diagnostics, Inc. Influenza vaccination
US9161905B2 (en) * 2005-01-12 2015-10-20 Ocular Research Of Boston, Inc. Dry eye treatment
TW200722101A (en) * 2005-03-23 2007-06-16 Glaxosmithkline Biolog Sa Novel composition
ATE526036T1 (en) * 2005-08-02 2011-10-15 Novartis Vaccines & Diagnostic REDUCING INTERFERENCE BETWEEN OIL ADJUVANTS AND SURFACTANT CONTAINING ANTIGENS
EA014062B1 (en) 2005-11-01 2010-08-30 Новартис Вэксинс Энд Диагностикс Гмбх & Ко Кг Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009514844A (en) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Emulsions containing free aqueous phase surfactants as adjuvants for split influenza vaccines
NZ567978A (en) 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
JP2009514839A (en) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Adjuvant influenza vaccine containing cytokine inducer
PL1945252T3 (en) 2005-11-04 2013-11-29 Seqirus Uk Ltd Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
PT1951299E (en) 2005-11-04 2012-02-28 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
JP6087041B2 (en) 2006-01-27 2017-03-08 ノバルティス アーゲー Influenza virus vaccine containing hemagglutinin and matrix protein
JP2009534303A (en) * 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー Preserving influenza vaccines that are not refrigerated
ATE522541T1 (en) 2006-06-09 2011-09-15 Novartis Ag BACTERIAL ADHESIN CONFORMERS
SI2043682T1 (en) 2006-07-17 2014-07-31 Glaxosmithkline Biologicals S.A. Influenza vaccine
PL2043682T3 (en) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Influenza vaccine
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA2663196A1 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
PL2086582T3 (en) 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Vaccine comprising an oil in water emulsion adjuvant
EP2679240A1 (en) 2006-12-06 2014-01-01 Novartis AG Vaccines including antigen from four strains of influenza virus
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
RU2468034C2 (en) 2007-08-27 2012-11-27 ЛОНГХОРН ВЭКСИНС ЭНД ДИАГНОСТИКС ЭлЭлСи Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
RU2496519C2 (en) * 2007-08-28 2013-10-27 Бакстер Интернэшнл Инк. Method for producing preparation containing viral antigens and using preparation
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
WO2009085355A2 (en) 2007-10-01 2009-07-09 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009081172A1 (en) 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
US8506966B2 (en) * 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
WO2009115917A2 (en) 2008-03-18 2009-09-24 Novartis Ag Improvements in preparation of influenza virus vaccine antigens
ES2553113T3 (en) 2008-04-16 2015-12-04 Glaxosmithkline Biologicals S.A. Vaccine
US20110217330A1 (en) 2008-11-05 2011-09-08 Bruno Rene Andre Novel method
EA023662B1 (en) 2009-02-10 2016-06-30 Новартис Аг Influenza vaccines with reduced amounts of squalene
SI2396030T1 (en) 2009-02-10 2015-12-31 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
US20120093860A1 (en) * 2009-02-10 2012-04-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
CA2763816A1 (en) 2009-04-27 2010-11-04 Novartis Ag Adjuvanted vaccines for protecting against influenza
AU2010250832B2 (en) 2009-05-21 2013-10-03 Seqirus UK Limited Reverse genetics using non-endogenous pol I promoters
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US9821052B2 (en) 2009-07-31 2017-11-21 Seqirus UK Limited Reverse genetics systems
CA2773637A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
CN102741399A (en) 2009-10-20 2012-10-17 诺华有限公司 Improved reverse genetics methods for virus rescue
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
AU2010325751B2 (en) 2009-12-03 2014-05-08 Seqirus UK Limited Arranging interaction and back pressure chambers for microfluidization
DE102009056884B4 (en) 2009-12-03 2021-03-18 Novartis Ag Vaccine Adjuvants and Improved Methods for Making Same
SI2506834T1 (en) 2009-12-03 2016-04-29 Novartis Ag Circulation of components during homogenization and microfluidization of emulsions
DE102009056871A1 (en) 2009-12-03 2011-06-22 Novartis AG, 4056 Vaccine adjuvants and improved methods of making the same
JP5754860B2 (en) 2009-12-03 2015-07-29 ノバルティス アーゲー Hydrophilic filtration during the manufacture of vaccine adjuvants
DE102009056883B4 (en) 2009-12-03 2012-08-16 Novartis Ag Vaccine adjuvants and improved methods of making the same
US20110305748A1 (en) 2010-03-11 2011-12-15 Immune Design, Corp. Vaccines for Pandemic Influenza
JP6072677B2 (en) 2010-05-06 2017-02-01 ノバルティス アーゲー Organic peroxide compounds for inactivation of microorganisms
EP2620423B2 (en) 2010-05-12 2019-07-31 Novartis AG Improved methods for preparing squalene
AU2011254204B2 (en) 2010-05-21 2015-08-20 Seqirus UK Limited Influenza virus reassortment method
AU2011262312B2 (en) 2010-06-01 2015-05-28 Novartis Ag Concentration and lyophilization of influenza vaccine antigens
KR20200057097A (en) 2010-06-01 2020-05-25 노파르티스 아게 Concentration of influenza vaccine antigens without lyophilization
WO2011154976A2 (en) 2010-06-08 2011-12-15 Panacea Biotec Limited Improved influenza vaccine
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
WO2012023044A1 (en) 2010-08-20 2012-02-23 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
WO2012032482A1 (en) 2010-09-07 2012-03-15 Novartis Ag Generic assays for detection of mammalian reovirus
JP6045499B2 (en) 2010-10-27 2016-12-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic composition comprising Shigella lipopolysaccharide and outer membrane protein
WO2012097346A1 (en) 2011-01-13 2012-07-19 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
CN103533923A (en) 2011-01-13 2014-01-22 变异生物技术公司 Methods for preparing vesicles and formulations produced therefrom
JP5798356B2 (en) * 2011-04-06 2015-10-21 一般財団法人化学及血清療法研究所 New influenza vaccine stabilizer
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
CA2852857A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
EP2780350B1 (en) 2011-11-18 2019-03-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc Compositions and methods for treating viral infections
CN104203272A (en) 2012-01-26 2014-12-10 长角牛疫苗和诊断有限责任公司 Composite antigenic sequences and vaccines
RU2698906C2 (en) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Methods and compositions for therapeutic agents
WO2013087945A2 (en) 2012-03-02 2013-06-20 Novartis Ag Influenza virus reassortment
GB201205189D0 (en) 2012-03-23 2012-05-09 Glaxosmithkline Biolog Sa Novel medical use
US20130315955A1 (en) * 2012-04-13 2013-11-28 Protein Sciences Corporation Stability and potency of hemagglutinin
US20150161359A1 (en) 2012-06-04 2015-06-11 Novartis Ag Methods for safety testing
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
AU2013354219A1 (en) 2012-12-03 2015-07-02 Novartis Ag Reassortant influenza a viren
MX2015008847A (en) 2013-01-10 2015-10-30 Novartis Ag Influenza virus immunogenic compositions and uses thereof.
CN105338999B (en) 2013-03-13 2020-02-28 诺华股份有限公司 Influenza B virus reassortment
KR20160030097A (en) 2013-05-10 2016-03-16 노파르티스 아게 Avoiding narcolepsy risk in influenza vaccines
DE202013005130U1 (en) 2013-06-05 2013-09-10 Novartis Ag Influenza virus reassortment
DE202013005100U1 (en) 2013-06-05 2013-08-26 Novartis Ag Influenza virus reassortment
AU2014276418A1 (en) 2013-06-06 2016-01-21 Novartis Ag Influenza virus reassortment
CN104436157A (en) 2013-09-23 2015-03-25 恩金生物有限公司 Influenza vaccine and therapy
WO2015079952A1 (en) 2013-11-29 2015-06-04 テルモ株式会社 Adjuvant composition, vaccine composition comprising same, and method for producing same
ES2861806T3 (en) 2014-12-02 2021-10-06 Novartis Ag Manufacture of surfactant-containing compositions
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
JP2018524323A (en) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド Antigen matched influenza vaccine
WO2017005880A1 (en) 2015-07-07 2017-01-12 Seqirus UK Limited Influenza potency assays
WO2017167768A1 (en) 2016-03-28 2017-10-05 Glaxosmithkline Biologicals S.A. Novel vaccine composition
GB201614799D0 (en) * 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
EP3917567A1 (en) 2019-01-30 2021-12-08 GlaxoSmithKline Biologicals SA Oil/surfactant mixtures for self-emulsification
CN115380107A (en) 2019-11-18 2022-11-22 思齐乐私人有限公司 Method for producing reassortant influenza viruses
RU2754398C1 (en) * 2020-06-25 2021-09-01 Общество с ограниченной ответственностью «ФОРТ» Method for obtaining a tetravalent vaccine for the prevention of influenza
US20230218526A1 (en) 2020-06-30 2023-07-13 Seqirus UK Limited Cold filtration of oil-in-water emulsion adjuvants

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520A (en) 1848-04-18 Oegan-pipb
US639A (en) 1838-03-17 of boston
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
DD155875A1 (en) 1980-12-31 1982-07-14 Willy Nordheim METHOD FOR PRODUCING A BALANCE-FREE INACTIVATED INFLUENZA VACCINE
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DD211444A3 (en) 1982-08-19 1984-07-11 Saechsisches Serumwerk PROCESS FOR THE PRODUCTION OF INFLUENZA VACCINES
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DD300833A7 (en) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd METHOD FOR THE PRODUCTION OF INACTIVATED INFLUENZA FULL VIRUS VACCINES
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
FR2638359A1 (en) 1988-11-03 1990-05-04 Tino Dalto SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN
NO902352L (en) * 1989-05-29 1990-11-30 Lion Corp PROCEDURE FOR THE PREPARATION OF A VACCINE AGAINST DENTAL KARIES, AND VACCINE MIXTURES FOR USE AS NOSE KILLS
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (en) 1991-09-13 1991-09-13 Kabi Pharmacia Ab INJECTION NEEDLE ARRANGEMENT
JP3723231B2 (en) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト Adjuvant
IL101007A (en) * 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
ATE188613T1 (en) 1992-06-25 2000-01-15 Smithkline Beecham Biolog VACCINE COMPOSITION CONTAINING ADJUVANTS
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
DE69619894T2 (en) 1995-06-30 2002-11-14 American Cyanamid Co., Madison Stable macrolides and macrolide vaccine compositions
US20020165168A1 (en) * 1995-12-16 2002-11-07 Joachim Bunger Use of sugar derivatives as antimicrobial, antimycotic and/or antiviral active substances
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5919480A (en) 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
DE19649895A1 (en) * 1996-12-02 1998-06-04 Henkel Kgaa Foaming body cleansers
CA2277911C (en) * 1997-01-13 2010-09-14 Emory University Compounds and their combinations for the treatment of influenza infection
GB9705740D0 (en) * 1997-03-20 1997-05-07 Medeva Europ Ltd A method of preservation
BR9811262A (en) 1997-04-01 2000-10-17 Ribi Immunochem Research Inc Aqueous immunological auxiliary compositions of monophosphoryl lipid a.
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
DE69815692T2 (en) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. OIL IN WATER EMULSIONS WITH SAPONINES
IT1298087B1 (en) 1998-01-08 1999-12-20 Fiderm S R L DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS
IL138000A0 (en) * 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
FR2780278B1 (en) * 1998-06-24 2001-01-19 Oreal CONDITIONING AND DETERGENT COMPOSITION AND USE
DE19841796A1 (en) 1998-09-12 2000-03-16 Beiersdorf Ag Combinations of antiadhesives (carbohydrates) and microbicides
IL145982A0 (en) * 1999-04-19 2002-07-25 Smithkline Beecham Biolog Vaccines
AUPQ233799A0 (en) * 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
BR0014285A (en) * 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvants comprising a polyoxyethylene alkyl ester or ether and at least one nonionic surfactant
CZ20021043A3 (en) * 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Use of polyoxyethylene sorbitan ester in combination with an octoxynol for preparing an auxiliary agent
EP1878424A3 (en) * 1999-09-24 2008-04-09 GlaxoSmithKline Biologicals S.A. Novel vaccine
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
ATE276749T1 (en) * 1999-10-19 2004-10-15 Procter & Gamble COMPOSITIONS FOR PREVENTING AND TREATING COLD AND FLU-LIKE SYMPTOMS AND THEIR USE
IL155073A0 (en) * 2000-10-02 2003-10-31 Glaxosmithkline Biolog Sa Split enveloped virus preparation
WO2002067983A1 (en) * 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US9856414B2 (en) 2013-06-10 2018-01-02 Dober Chemical Corp. Compositions, systems and methods of making coated additive components

Also Published As

Publication number Publication date
HUP0400445A3 (en) 2011-06-28
US20080181914A1 (en) 2008-07-31
HK1067891A1 (en) 2005-04-22
KR20040025682A (en) 2004-03-24
NO20035208D0 (en) 2003-11-24
KR100871021B1 (en) 2008-11-27
CN101069744B (en) 2012-04-25
DE60230760D1 (en) 2009-02-26
PL206435B1 (en) 2010-08-31
WO2002097072A8 (en) 2004-02-19
ES2318020T3 (en) 2009-05-01
AR036039A1 (en) 2004-08-04
US20040241187A1 (en) 2004-12-02
CY1108930T1 (en) 2014-07-02
NO335212B1 (en) 2014-10-20
ATE420159T1 (en) 2009-01-15
AU2002344182C1 (en) 2014-11-06
EP1407008A2 (en) 2004-04-14
AU2002344182B2 (en) 2006-01-05
AU2006200742C9 (en) 2015-03-26
BRPI0210076A8 (en) 2017-05-23
WO2002097072A2 (en) 2002-12-05
CZ298697B6 (en) 2007-12-27
CN1279165C (en) 2006-10-11
AU2006200742C1 (en) 2014-10-16
DK1407008T3 (en) 2009-04-27
PL366990A1 (en) 2005-02-07
EP1407008B1 (en) 2009-01-07
CA2448208A1 (en) 2002-12-05
IL188834A0 (en) 2009-02-11
US7316813B2 (en) 2008-01-08
CN101069744A (en) 2007-11-14
EP2495314A1 (en) 2012-09-05
MXPA03010944A (en) 2005-04-08
CO5540349A2 (en) 2005-07-29
HU229368B1 (en) 2013-11-28
NZ529755A (en) 2005-11-25
JP4074582B2 (en) 2008-04-09
MY134424A (en) 2007-12-31
BRPI0210076B8 (en) 2021-05-25
BR0210076A (en) 2004-06-22
JP2004527264A (en) 2004-09-09
EP2039761A1 (en) 2009-03-25
AU2006200742B2 (en) 2010-05-27
CA2448208C (en) 2011-11-29
AU2006200742A1 (en) 2006-03-16
ZA200309250B (en) 2005-05-25
CN1533434A (en) 2004-09-29
TWI228420B (en) 2005-03-01
IL158931A (en) 2008-04-13
BRPI0210076B1 (en) 2020-01-07
PT1407008E (en) 2009-02-26
SI1407008T1 (en) 2009-06-30
HUP0400445A2 (en) 2004-07-28
IL188834A (en) 2011-01-31
WO2002097072A3 (en) 2003-04-24
CZ20033253A3 (en) 2004-04-14

Similar Documents

Publication Publication Date Title
FR13C0072I1 (en) NEW VACCINE COMPOSITION
ATE553775T1 (en) VACCINE COMPOSITION
NO20050132D0 (en) vaccine Composition
NO20026175L (en) vaccine Composition
NO20052010D0 (en) Immunogenic composition
FI20011478A (en) Pharmaceutical composition
FR2824267B1 (en) COSMETIC COMPOSITION FILMOGENE
ATE490327T1 (en) VACCINE COMPOSITION
DK1427444T3 (en) WEST-NIL VACCINE
IS6915A (en) composition
BR0210619A (en) composition
NO20033882L (en) Vaccine
IS7051A (en) pharmaceutical compositions
IS7081A (en) composition
DK1368456T3 (en) Antibacterial vaccine compositions
NO20040860L (en) Pharmaceutical composition including lumiracoxib
FI20022128A0 (en) Pharmaceutical composition
FR2819176B1 (en) COSMETIC PELABLE COMPOSITION
FR2830751B1 (en) COSMETIC COMPOSITION FILMOGENE
DK1429753T3 (en) Pharmaceutical composition comprising gamma-butyrobetaine
ITTO20020744A0 (en) COMPOSITION
SE0100847D0 (en) Novel pharmaceutical composition
FI5468U1 (en) Pharmaceutical composition
SE0100478D0 (en) Novel formulation
SE0100477D0 (en) Novel formulation